With more than 100 translocation partners, KMT2A rearrangement (KMT2A-r) can lead to ALL, acute myeloid leukemia (AML), and mixed phenotypic acute leukemia (MPAL), with dismal prognosis across all categories.2–5. This evidence concerns the gene KMT2A and acute myeloid leukemia.